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The Indian blood group system
Q. Xu
The Indian blood group system (ISBT: IN/023) consists of two 
antithetical antigens: Ina (IN1), which is present in approximately 
10 percent of some Arab populations and in 3 percent of Bombay 
Indians, and its allelic antigen Inb (IN2), an antigen of high 
incidence in all populations. In 2007, two new high-incidence 
antigens were identified as belonging to the IN blood group system, 
namely IN3 (INFI) and IN4 (INJA). The antigens in this system 
are located on CD44, a single-pass membrane glycoprotein that 
is encoded by the CD44 gene on chromosome 11 at position p13. 
The biologic function of CD44 is as a leukocyte homing receptor 
and cellular adhesion molecule. The Ina and Inb polymorphism 
represents a 252G>C substitution of CD44, encoding R46P, and 
lack of IN3 and IN4 results from homozygosity for mutations 
encoding H85Q and T163R in the CD44 gene. The high-frequency 
antigen AnWj (901009) has not been assigned to the Indian 
system, but either is located on an isoform of CD44 or is closely 
associated with it. Immunohematology 2011;27:89–93.
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History
The first antigen of the Indian blood group system, Ina, 
was described in 1973 by Badakere et al.1,2 and named for its 
finding in an Indian population. Ina is a low-incidence antigen 
that was present on the red blood cells (RBCs) of about 3 
percent of random Indian donors from Bombay.1,2 Two years 
later, Giles3 noted that the Pakistan-origin serum Salis, which 
is an antibody to a high-incidence antigen that had remained 
unsolved for 12 years since its discovery in 1963, had an 
antithetical relationship to anti-Ina and therefore named it 
anti-Inb. The Indian antigens were formally approved to be an 
independent blood group system by the International Society 
of Blood Transfusion (ISBT) Committee on Terminology for 
RBC surface antigens in 1995.4 There were only two antigens, 
Ina and Inb, in the Indian system until 2007, when two new 
high-incidence antigens were identified as belonging to the IN 
blood group system, namely IN3 (INFI) and IN4 (INJA).5
In 1988, Spring and colleagues6 demonstrated by 
immunoblotting that Ina and Inb were carried on the leukocyte 
homing receptor and cellular adhesion molecule, CD44, which 
was encoded by CD44 located on chromosome 11 at 11p13. 
The Ina/Inb polymorphism arises from the substitution of 
one amino acid, from Pro to Arg at position 46 of the CD44 
protein, which resulted from a single mutation G>C in CD44 
at position 252.7
Between 1972 and 1982, many antibodies were found to 
define the same high-incidence antigen, named Anton.8–10 In 
1983 an autoantibody, anti-Wj, was found to detect the same 
specificity as anti-Anton11; the antigen later was renamed 
AnWj.12 AnWj is located in the 901 ISBT high-incidence 
antigen series. There is strong evidence that AnWj might be 
carried on an isoform of CD44, although it is not formally 
included in the Indian system.13–15
Nomenclature
In 1995, the Indian blood group system was formally 
recognized as an independent blood group system and given 
conventional and ISBT terminology.4 Ina and Inb were given 
the antigen numbers IN1 and IN2. In 2007, two new antigens, 
IN3 and IN4, were added to this system (Table 1).5
Genetics and Inheritance
Ina is a low-incidence antigen. Of 1749 Indians, 51 (3%) 
were In(a+).2 A higher incidence of Ina was found in 59 of 557 
(10.6%) Iranians and 29 of 246 (11.8%) Arabs in Bombay.16 
Based on the incidence of Ina, the In(a+b–) phenotype would 
be expected to be extremely rare in certain populations. 
However, 2 of 700 Indian blood donors were In(b–), whereas 
2 of 251 donors from the Asian immigrant population of 
northern England were In(a+b–), showing a greater incidence 
of In(a+b–) than that expected from the incidence of Ina 
(Table 2).2,16–19 From the limited number of families reported, 
Ina and Inb appear to be inherited as codominant autosomal 
alleles.2,3,20 When a girl with In(a–b–) phenotype experienced 
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Table 1. Indian blood group system and AnWj antigens
Historical name Conventional name ISBT symbol ISBT No.
Ina IN1 023001
Salis Inb IN2 023002
INFI IN3 023003
INJA IN4 023004
Anton(Lu15) and Wj AnWj AnWj 901009
ISBT = International Society of Blood Transfusion.
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congenital dyserythropoietic anemia that was associated with 
a deficiency of erythrocyte CD44, her RBCs also typed as 
Co(a–b–) and AnWj–, and were weak for LWa and LWb. The 
patient’s parents and sister were In(a–b+), giving no evidence 
as to whether the phenotype In(a–b–) is inherited or related to 
her disease.13
The rare AnWj– phenotype is usually acquired and 
may be transient, but in 1991 Poole et al.21 showed that it 
could also be inherited. RBCs from two of seven siblings of 
an AnWj– Arab woman with anti-AnWj were AnWj–. The 
consanguineous parents and the six children of the proposita 
were AnWj+, suggesting that the AnWj– phenotype in this 
family results from homozygosity of a rare recessive gene. The 
family study demonstrated that AnWj is not controlled by LU, 
or by ABO, MNS, RH, KEL, FY, JK, XG, or XK. Screening of 
RBCs from 2400 American donors for AnWj revealed three 
Lunull In(Lu) samples whose RBCs initially failed to react with 
anti-AnWj but could be shown to bind that antibody and yield 
it on elution; however, no AnWj– RBCs with normal Lutheran 
antigens were found.22
Molecular Basis
Ina and Inb are carried on the CD44 glycoprotein, which 
is encoded by CD44.7 CD44 is located on the short arm of 
chromosome 11 (11p13),23 spans 50 to 60 kb of DNA, and 
consists of 20 exons.24 CD44 exists as multiple isoforms, 
arising partly from alternative splicing of at least 10 of the 20 
exons during processing of the CD44 transcript and partly 
from variation in glycosylation.24,25 CD44H (hemopoietic), the 
standard form of the molecule, is the CD44 isoform present 
on RBCs and leukocytes. CD44H comprises the products of 
exons 1 through 5, 15 through 17, and 19 (Fig. 1). Exons 6 
through 14 are alternatively spliced in and encode CD44 
isoforms found on other cells. The exons encoding the distal-
link protein homology domain are conserved in all forms of 
the molecule. Tissue-specific variants are created by splicing 
in exons that enlarge the proximal extracellular domain. 
Alternative splicing of exons encoding the cytoplasmic domain 
has also been reported.24,26
The Ina/Inb polymorphism results from a single base 
change in exon 2 of CD44 encoding an amino acid substitution; 
the common allele, Inb, has G252 and encodes Arg46; Ina has 
C252 and encodes Pro46.7 The Jurkat human leukemia cell 
line was transfected with CD44 complementary DNA (cDNA) 
constructs from Inb or Ina alleles, or from the Inb allele with 
a G252C change introduced by site-directed mutagenesis. 
All three types of transfectant produced CD44 protein, but 
only cells transfected with the wild-type cDNA Inb sequence 
expressed Inb. Other changes detected in some In(a+b–) 
individuals (T322C, silent; T370C, silent; A441C, Tyr109Ser; 
A831G, Glu239Gly) do not appear to affect expression of the 
Indian antigens.27
Two novel antigens, IN3 (INFI) and IN4 (INJA), of high 
incidence have been identified in the Indian blood group 
system. Lack of IN3 and IN4 results from homozygosity for 
mutations encoding H85Q and T163R in the CD44 gene, 
respectively. Anti-IN3 and anti-IN4 have been produced by 
three and two individuals, respectively, whose RBCs lack the 
corresponding antigen.5
Biochemistry
Spring and colleagues6 used immunoblotting with eluates 
of human anti-Ina and anti-Inb to show that Ina and Inb were 
located on a molecule of an apparent molecular weight of 80 
kDa in RBC membranes. In the same paper, these authors 





Caucasians 0.1% 99% Rare 99.9% <0.1%
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Indians (South Asians) 4.0% 96% Rare 96% 4%
Asian Immigrants in 
Northern England
4.0%
Iranians 10.6% Rare 90% 10%
Arabs 11.8% Rare 90% 10%
Figure 1. Structure of the CD44 gene.18,24 A minor hemopoietic 
form of CD44 results from the splicing in of the product of exon 18. 
This results in a form of CD44 with a cytoplasmic tail of only 3 amino 
acids.  are constitutive exons;  are alternative exons;  indicate 
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showed that this molecule was identical to a glycoprotein 
known as CD44. CD44 had been defined by a cluster analysis 
of murine monoclonal antibodies. The first monoclonal anti-
CD44 to be reported was F10.44.2, an antibody originally 
described as reactive with an antigen on human brain cells, 
granulocytes, and T lymphocytes.28 Spring et al.6 showed that 
CD44 purified using F10.44.2 would bind human anti-Inb. 
Since that time, CD44 has been extensively studied, and it is 
now established as a major adhesion molecule present on the 
surface of numerous different cell types.
The molecular basis of the Ina/Inb polymorphism was 
not established until 1996, when Telen et al.7 reported that a 
single point mutation in CD44 (G252 to C) resulted in a single 
amino acid substitution in the polypeptide chain of the CD44 
molecule (Arg46 to Pro). The presence of Arg46 correlated 
with Inb expression, and Pro46, with Ina expression. Formal 
proof that Arg46 is the critical residue for Inb was obtained 
by expression studies. Jurkat cells were transfected with 
wild-type cDNA having Arg46, cDNA from an In(a+b–) 
individual having Pro46, and wild-type cDNA in which 
Arg46 was changed to Pro by site-directed mutagenesis. 
The latter construct was necessary because the cDNA from 
the In(a+b–) individual shows five nucleotide sequences that 
were changed from that of the wild type, and three of these 
predicted single amino acid differences (Arg46 to Pro, Tyr109 
to Ser, and Glu239 to Gly). It was therefore necessary to 
examine the possible role of Arg46Pro in the absence of the 
other changes. When the transfected cells were tested with 
human anti-Inb by flow cytometry, only the cells expressing 
the wild-type cDNA were reactive. These results establish that 
Arg46 is critical for Inb expression, but because the transfected 
cells were not tested with anti-Ina, a role for the other amino 
acid changes (at residues 109 and 239) in the structure of Ina 
cannot formally be excluded. The tertiary structure of CD44 is 
not known, but models of the protein deduced from available 
structural information suggest that residues 109 and 239 are 
likely to be distant from Pro46 and are therefore unlikely to 
be involved in Ina expression (Fig. 2). Ina is rare outside the 
indigenous peoples of India, Pakistan, and the Middle East. If 
the wild-type cDNA used in these studies was derived from an 
individual of a different ethnic group, it is possible that some 
or all of the other amino acid sequence changes observed are a 
reflection of the different ethnic origins of the cDNAs.18
Antibodies in the System
Indian antigens appear to be good immunogens. Thirty of 
39 In(a–) donors immunized for anti-D production with D+ 
In(a+) RBCs made anti-Ina.29 Anti-Ina has also been produced 
in response to transfusion of a unit of In(a+) blood.30 One 
anti-Inb was produced in an untransfused woman during her 
first pregnancy.20 Anti-Ina and anti-Inb agglutinate antigen-
positive RBCs directly, although the strength of the reaction is 
generally enhanced by antiglobulin.3,17,29
Radiolabelled In(a+) RBCs were eliminated from the 
circulation of two individuals with anti-Ina within 20 minutes, 
suggesting the potential for a transfusion reaction.29 There 
is one case of anti-Inb causing an immediate hemolytic 
transfusion reaction after infusion of 50 mL of incompatible 
blood.31 Reduced in vivo survival of In(b+) cells in a patient 
with anti-Inb was observed at 24 hours.20 Neither anti-Ina nor 
anti-Inb has been reported to cause hemolytic disease of the 
fetus and newborn (HDFN). In(b+) cord cells from babies 
born to mothers with immunoglobulin G1 anti-Inb do not 
usually give a positive direct antiglobulin test (DAT), and anti-
Inb cannot usually be detected in the infants’ sera.17,20,32 In one 
case with maternal anti-Inb of high titer, RBCs obtained from 
the baby yielded a positive DAT, and anti-Inb could be eluted 
from them.33 However, there was no sign of hemolytic disease 
of the newborn, and it is postulated that binding of anti-Inb 
to CD44 on fetal monocytes and macrophages could have a 
blocking effect on FcγR1.33
Clinical Significance
Anti-Ina has not been reported to cause a hemolytic 
transfusion reaction so far, perhaps because the In(a–) 
phenotype is predominant in all populations and patients 
with anti-Ina are unlikely to be transfused with In(a+) blood. 
However, in vivo survival studies showed radiolabelled In(a+) 
RBCs to be rapidly removed in two patients with anti-Ina, 
suggesting an occurrence of a hemolytic transfusion reaction.29
Figure 2. Model of CD44H.27 The 
extracellular domain consists of two 
regions: a membrane-proximal region 
containing one N-glycosylation site 
(N), several O-glycosylation sites 
(O), and several Ser-Gly chondroitin 
sulfate linkage sites (SG); and 
a distal region containing five 
N-glycosylation sites and six cysteine 
residues (C), which suggests the 
presence of three disulfide bonds 
(S–S). The position of the amino 
acid substitution responsible for the 
Ina/Inb polymorphism is shown.
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Joshi et al.31 reported an immediate hemolytic transfusion 
reaction in a patient with anti-Inb who was transfused with 
50 mL of In(b+) blood. Another case report on anti-Inb and 
in vivo cell survival showed destruction of transfused In(b+) 
RBCs by the antibody.20
There is no reported HDFN caused by either anti-Ina 
or anti-Inb antibody so far. The finding that anti-Inb cannot 
cause HDFN perhaps can be attributed to the fact that anti-
Inb may have been adsorbed by CD44 from placental or fetal 
tissues. CD44 is also involved in binding hyaluronan, collagen, 
fibronectin, and laminin and plays a varied clinical role.
Antibodies to AnWj have been reported to cause severe 
hemolytic transfusion reactions or immune hemolytic 
anemia in cases in which the patients had Waldenstrom 
macroglobulinemia, non-Hodgkin lymphoma, and ovary 
carcinoma.34–36 In in vivo RBC survival studies, the AnWj 
antibodies were demonstrated to cause accelerated clearance 
of AnWj+ RBCs.37 Because AnWj was expressed very weakly 
on the RBCs of an individual with the dominant gene In(Lu), if 
available, In(Lu) Lunull cells might be expected to survive better 
in a patient with anti-AnWj than random AnWj+ RBCs.18 
AnWj was also reported to be the receptor for Haemophilus 
influenzae, and anti-AnWj inhibited agglutination of AnWj+ 
RBCs by the bacteria.
There is no indication that anti-AnWj could cause HDFN. 
In the first family in which the recessive type of AnWj– was 
recognized, both the proposita and her sister had anti-AnWj in 
their sera. They had no transfusion history, but both had been 
pregnant. The proposita’s anti-AnWj did not cause HDFN in 
any of her children. Their brother, with AnWj– RBCs and no 
transfusion history, did not produce anti-AnWj in his serum.21 
Anti-AnWj could be stimulated by low-level AnWj on neonatal 
RBCs, demonstrating that it is a good immunogen.
Summary
The Indian blood group system is a polymorphism in 
people from the Indian and Arabian populations. The blood 
group phenotypes in this system are attributable to mutations 
in the gene for CD44. Immediate hemolytic transfusion reaction 
has been reported in patients with anti-Inb antibodies, but as 
yet no HDFN case has been reported to be caused by antibody 
in this system. Variants in the system are found through 
identification of serologic anomalies in transfusion reference 
laboratories and can be valuable in providing information 
about the structures and functions of cell surface molecules.
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